Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 3.15
LXRX's Cash to Debt is ranked higher than
62% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. LXRX: 3.15 )
LXRX' s 10-Year Cash to Debt Range
Min: 1.85   Max: No Debt
Current: 3.15

Equity to Asset 0.60
LXRX's Equity to Asset is ranked higher than
67% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. LXRX: 0.60 )
LXRX' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.94
Current: 0.6

0.36
0.94
F-Score: 3
Z-Score: -0.68
M-Score: 4.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -439.16
LXRX's Operating margin (%) is ranked higher than
60% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. LXRX: -439.16 )
LXRX' s 10-Year Operating margin (%) Range
Min: -9955.46   Max: -47.73
Current: -439.16

-9955.46
-47.73
Net-margin (%) -438.85
LXRX's Net-margin (%) is ranked higher than
60% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. LXRX: -438.85 )
LXRX' s 10-Year Net-margin (%) Range
Min: -10120.39   Max: -47.98
Current: -438.85

-10120.39
-47.98
ROE (%) -63.52
LXRX's ROE (%) is ranked higher than
62% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. LXRX: -63.52 )
LXRX' s 10-Year ROE (%) Range
Min: -63.41   Max: -16.51
Current: -63.52

-63.41
-16.51
ROA (%) -35.80
LXRX's ROA (%) is ranked higher than
67% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. LXRX: -35.80 )
LXRX' s 10-Year ROA (%) Range
Min: -32.59   Max: -15.27
Current: -35.8

-32.59
-15.27
ROC (Joel Greenblatt) (%) -373.92
LXRX's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. LXRX: -373.92 )
LXRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -490.12   Max: -42.53
Current: -373.92

-490.12
-42.53
Revenue Growth (3Y)(%) 58.70
LXRX's Revenue Growth (3Y)(%) is ranked higher than
97% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. LXRX: 58.70 )
LXRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -100   Max: 58.7
Current: 58.7

-100
58.7
EBITDA Growth (3Y)(%) -17.50
LXRX's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. LXRX: -17.50 )
LXRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -28.7   Max: 22.6
Current: -17.5

-28.7
22.6
EPS Growth (3Y)(%) -17.60
LXRX's EPS Growth (3Y)(%) is ranked higher than
68% of the 803 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. LXRX: -17.60 )
LXRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -26.1   Max: 30.8
Current: -17.6

-26.1
30.8
» LXRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

LXRX Guru Trades in Q1 2014

Mario Gabelli 143,200 sh (unchged)
Chuck Royce 4,233,933 sh (unchged)
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
Jim Simons Sold Out
Paul Tudor Jones 24,640 sh (-21.45%)
» More
Q2 2014

LXRX Guru Trades in Q2 2014

Mario Gabelli 160,200 sh (+11.87%)
Paul Tudor Jones 24,640 sh (unchged)
Chuck Royce 2,886,133 sh (-31.83%)
» More
Q3 2014

LXRX Guru Trades in Q3 2014

Paul Tudor Jones 29,223 sh (+18.60%)
Mario Gabelli 160,200 sh (unchged)
Chuck Royce 2,736,133 sh (-5.20%)
» More
Q4 2014

LXRX Guru Trades in Q4 2014

Jim Simons 695,910 sh (New)
Paul Tudor Jones 53,297 sh (+82.38%)
Chuck Royce 2,813,833 sh (+2.84%)
Mario Gabelli 105,200 sh (-34.33%)
» More
» Details

Insider Trades

Latest Guru Trades with LXRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.70
LXRX's P/B is ranked higher than
85% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. LXRX: 2.70 )
LXRX' s 10-Year P/B Range
Min: 0.66   Max: 5.28
Current: 2.7

0.66
5.28
P/S 25.72
LXRX's P/S is ranked higher than
60% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 36.81 vs. LXRX: 25.72 )
LXRX' s 10-Year P/S Range
Min: 2.64   Max: 293
Current: 25.72

2.64
293
Current Ratio 8.21
LXRX's Current Ratio is ranked higher than
84% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. LXRX: 8.21 )
LXRX' s 10-Year Current Ratio Range
Min: 1.19   Max: 19.93
Current: 8.21

1.19
19.93
Quick Ratio 8.21
LXRX's Quick Ratio is ranked higher than
85% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. LXRX: 8.21 )
LXRX' s 10-Year Quick Ratio Range
Min: 1.19   Max: 19.93
Current: 8.21

1.19
19.93
Days Sales Outstanding 16.53
LXRX's Days Sales Outstanding is ranked higher than
95% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 134.01 vs. LXRX: 16.53 )
LXRX' s 10-Year Days Sales Outstanding Range
Min: 5.95   Max: 461.86
Current: 16.53

5.95
461.86

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.20
LXRX's Price/Net Cash is ranked higher than
88% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 103.40 vs. LXRX: 5.20 )
LXRX' s 10-Year Price/Net Cash Range
Min: 2.83   Max: 35.98
Current: 5.2

2.83
35.98
Price/Net Current Asset Value 5.20
LXRX's Price/Net Current Asset Value is ranked higher than
86% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 42.30 vs. LXRX: 5.20 )
LXRX' s 10-Year Price/Net Current Asset Value Range
Min: 2.45   Max: 59.65
Current: 5.2

2.45
59.65
Price/Tangible Book 4.20
LXRX's Price/Tangible Book is ranked higher than
79% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. LXRX: 4.20 )
LXRX' s 10-Year Price/Tangible Book Range
Min: 0.89   Max: 40.25
Current: 4.2

0.89
40.25
Price/Median PS Value 1.80
LXRX's Price/Median PS Value is ranked higher than
73% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. LXRX: 1.80 )
LXRX' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 10.29
Current: 1.8

0.21
10.29
Earnings Yield (Greenblatt) -18.10
LXRX's Earnings Yield (Greenblatt) is ranked lower than
56% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. LXRX: -18.10 )
LXRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -25.5   Max: 0
Current: -18.1

-25.5
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:LX3.Germany,
Lexicon Pharmaceuticals Inc was incorporated in Delaware on July 7, 1995. The Company operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease. It has used its proprietary gene knockout technology and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. It has identified and validated in living animals, or in vivo, more than 100 targets with promising profiles for drug discovery. The Company has also advanced small molecule compounds from a number of additional drug programs into various stages of preclinical development and research and believe that its systematic, target biology-driven approach to drug discovery will enable it to continue to expand its clinical pipeline. It faces significant competition in each of the aspects of its business from other pharmaceutical and biotechnology companies. The development, manufacture and sale of any drug or biologic products developed by the Company or its collaborators will be subject to extensive regulation by United States and foreign governmental authorities, including federal, state and local authorities.
» More Articles for LXRX

Headlines

Articles On GuruFocus.com
Lexicon Genetics Inc. Reports Operating Results (10-Q) Nov 08 2010 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Lexicon Genetics Inc. Reports Operating Results (10-Q) May 10 2010 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Oct 30 2009 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Aug 06 2009 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Apr 30 2009 


More From Other Websites
LEXICON PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Apr 23 2015
Lexicon Pharmaceuticals and Bristol-Myers Squibb Select Development Candidate for Neuropathic Pain... Apr 15 2015
Lexicon Pharmaceuticals and Bristol-Myers Squibb Select Development Candidate for Neuropathic Pain... Apr 15 2015
Lexicon to Present at Needham & Company's 14th Annual Healthcare Conference Apr 09 2015
Lexicon To Present At Needham & Company's 14th Annual Healthcare Conference Apr 09 2015
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) to Ring The Nasdaq Stock Market Closing Bell Apr 07 2015
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) to Ring The Nasdaq Stock Market Closing Bell Apr 07 2015
Lexicon Pharmaceuticals (LXRX): Strong Industry, Solid Earnings Estimate Revisions - Tale of the... Apr 02 2015
Lexicon Pharmaceuticals Announces First Patient Screened in Pivotal Phase 3 Clinical Trial of... Mar 25 2015
Lexicon Pharmaceuticals Announces First Patient Screened In Pivotal Phase 3 Clinical Trial Of... Mar 25 2015
Lexicon-Ipsen Agreement Expanded to Include Canada - Analyst Blog Mar 19 2015
LEXICON PHARMACEUTICALS, INC. Financials Mar 19 2015
LEXICON PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Mar 18 2015
Lexicon and Ipsen Expand Their Licensing and Commercialization Agreement for Telotristat Etiprate to... Mar 18 2015
Lexicon and Ipsen Expand Their Licensing and Commercialization Agreement for Telotristat Etiprate to... Mar 18 2015
Lexicon and Ipsen Expand Their Licensing and Commercialization Agreement for Telotristat Etiprate to... Mar 18 2015
Lexicon Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of Telotristat... Mar 16 2015
LEXICON PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report Mar 12 2015
Lexicon Pharmaceuticals Completes Enrollment In Pivotal Phase 3 Clinical Trial Of Telotristat... Mar 09 2015
Lexicon tops Street 4Q forecasts Mar 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK